News | January 17, 2012

Microscopic Sponge-Type Particles Zap Nosebleeds

January 17, 2012 – Nonstop nosebleeds can be serious and frightening, often sending people to the emergency room, where their noses are packed with gauze. When that doesn’t work, nosebleeds can be halted by injecting microscopic particles – made of the same material as a kitchen sponge – into the arteries that supply the nose. The more blood vessels blocked the better, suggests research being presented at the 24th annual International Symposium on Endovascular Therapy (ISET).

Worldwide, 60 percent of people have suffered nosebleeds, 6 percent of them so severely that they sought medical treatment. These unstoppable nosebleeds are most likely to occur in people who have high blood pressure or are taking blood thinners. Severe anemia from blood loss can lead to complications such as heart attack. Typical nosebleed treatment is to temporarily pack the nose with gauze, inflate a balloon to stop the blood flow or cauterize the blood vessels inside the nose. If those treatments fail, the next options are surgery, or minimally invasive embolization, in which polyvinyl alcohol (PVA) particles are injected into the blood vessels to the nose.

In a study, 84 patients had one to four blood vessels embolized. Nosebleed recurrence rates decreased as more blood vessels were embolized: 2 of 8 (25 percent) who had one blood vessel treated experienced recurrence as did 5 of 35 (14 percent) who had two vessels treated and 2 of 32 (6 percent) who had three vessels treated. None of nine who had four vessels treated experienced a recurrence. Minor pain and complications increased with the numbers of vessels embolized, including mild facial pain, swelling and headache, but were temporary and treated with pain medication.

“Embolization is less invasive than surgery and is very successful, taking the pressure off the fragile lining of the nose and allowing it to heal before the arteries eventually partially reopen,” said Colin P. Derdeyn, M.D., director of the Stroke and Cerebrovascular Center at

Washington University School of Medicine, Barnes Jewish Hospital, St. Louis, Mo. “Our research suggests that the more vessels you embolize, the more successful the treatment.”

To embolize the blood vessels, an interventional radiologist threads a catheter into a groin artery and advances it through the body to one or more of the four arteries that supply the nose, injecting the PVA particles. The particles temporarily stop the blood flow, halting the nosebleed and allowing the area to heal. PVA has been used safely in the body for about 50 years.

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init